The Danish pharmaceutical giant Novo Nordisk, known for the popular slimming prick Ozempic, warns against considerably lower profit expectations in 2025. Due to increasing competition, decreasing user -convenience and growing concerns about safety, the figures push. The share lost more than 21 percent on the stock exchange in Copenhagen on Tuesday.
ttn-42
Ozempic Maker warns against lean sales and profit this year: share more than 21 percent lower
Bytaketonews
Jul 29, 2025